Author(s): Shawyer A, Fotiadis NI, Namagondlu G, Iyer A, Blunden M,
Abstract Share this page
Abstract PURPOSE: Cephalic arch stenosis (CAS) is an important and common cause of dysfunction in autogenous haemodialysis fistulas that requires multiple reinterventions and aggressive surveillance. We evaluated the safety and efficacy of the Viabahn stent-graft for the management of CAS. METHODS: Between April 2005 and October 2011, 11 consecutive patients [four men and seven women (mean age 56.7 years)] with CAS and dysfunctional fistulas were treated with insertion of 11 Viabahn stent-grafts. Six stent-grafts were inserted due to residual stenosis after angioplasty and five for fistuloplasty-induced rupture. No patient was lost to follow-up. RESULTS: The technical and clinical success rate was 100 \%. Primary access patency rates were 81.8 \% [95 \% confidence interval (CI) 0.482-0.977] at 6 months and 72.7 \% (95 \% CI 0.390-0.939) at 12 months. Secondary access patency rates were 90.9 \% at 6 months (95 \% CI 0.587-0.997). There were no procedure-related complications. Mean follow-up was 543.8 days (range 156-2,282). CONCLUSION: The use of the Viabahn stent-graft in the management of CAS is technically feasible and, in this small series, showed patency rates that compare favorably with historical data of angioplasty and bare stents.
This article was published in Cardiovasc Intervent Radiol
and referenced in Journal of Antivirals & Antiretrovirals